Navigation Links
Cell Therapeutics Announces Study Data Set Cut-off for Phase III Pivotal Pixantrone (301) Trial
Date:11/2/2008

Novartis notified of data set closing, Top-line results expected in

November

SEATTLE, Nov. 3 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that it has closed the data set for preliminary analysis of the primary endpoint in the phase III EXTEND (PIX301) trial of pixantrone (BBR2278) for patients with relapsed diffuse large B cell non-Hodgkin's lymphoma (NHL) and it has provided Novartis notice that the data set has been closed. The primary endpoint for the study is the complete remission (CR) and unconfirmed complete remission (uCR) rate in patients receiving either pixantrone or another single agent chemotherapeutic drug. CTI plans to report top-line results in November.

"We are excited to have reached the end of the treatment phase and follow-up period for the pixantrone pivotal study and look forward to reporting top-line results in November," said James A. Bianco, M.D., CEO of Cell Therapeutics. "Complete remissions in this patient population with end stage advanced disease are seldom accomplished with the current standard of care. Pixantrone, if successful in achieving the study objectives, could offer these patients a significant benefit, and we would work with the FDA to submit an NDA in 2009."

CTI has an existing license and co-development agreement with Novartis for OPAXIO(TM) (paclitaxel poliglumex, CT-2103), which also provides Novartis with an option to enter into an exclusive worldwide license to develop and commercialize pixantrone based upon agreed terms.

About the EXTEND (PIX301) Clinical Trial

The EXTEND clinical trial is a phase III single agent trial of pixantrone for patients with relapsed, aggressive non-Hodgkin's lymphoma who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial was conducted at 130 sites in 17 countries. Patients were randomized to receive either pixantr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. InteRNA Technologies and VU University Medical Center to Develop microRNA-Based Diagnostics and Therapeutics for Cancer
2. Sirion Therapeutics Announces Positive Pivotal Uveitis Data for Durezol(TM)
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting
5. In Vivo Data on Taligen Therapeutics Pipeline Candidates Presented at the XXII International Complement Workshop
6. BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
7. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
8. Orexigen(R) Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R)
9. PTC Therapeutics Announces Data Showing Six-Minute Walk Test Consistently Measures Ambulatory Function in Patients With Duchenne Muscular Dystrophy
10. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
11. Data Confirm Synvista Therapeutics Haptoglobin Diagnostic Test Kit Success in Rapidly Determining Cardiovascular Risk in Patients with Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... experimental drug designed to help regulate the blood,s iron supply ... inflammation, according to results from the first human study ... Blood , the Journal of the American Society ... condition that occurs when red blood cells are in short ... anemia, the body does not get enough oxygen, since there ...
(Date:8/27/2014)... Kewaunee Scientific Corporation (Nasdaq: KEQU ... quarterly cash dividend by 9% to twelve cents per ... with the dividend payable on September 22, 2014 to ... September 8, 2014. About Kewaunee Scientific ... Corporation is a recognized global leader in the design, ...
(Date:8/27/2014)... NINGBO, China , Aug. 27, 2014 /PRNewswire/ ... Co., Ltd, ("Menovo") today announced they had entered into ... primarily targeting the United States ... Menovo will jointly develop products for Amerigen to commercialize ... will be responsible for manufacturing API and finished product ...
Breaking Medicine Technology:Drug Represents First Potential Treatment for Common Anemia 2Drug Represents First Potential Treatment for Common Anemia 3Amerigen Pharmaceuticals Limited and the Ningbo Menovo Pharmaceutical Co., Ltd, today announced they had entered into a collaboration agreement regarding the development of generic pharmaceuticals, primarily targeting the United States market 2
... ORANGE COUNTY, Calif., Nov. 23 Beckman Coulter, Inc. ... and marketer of products that simplify, automate, and innovate ... Coulter,s vice president of strategy, will present at the ... at 12:00 p.m. (ET). , (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) ...
... , NEW ... market research report is available in its catalogue. , ... 2015 , http://www.reportlinker.com/p0164603/The-Future-of-the-Diagnostic-Imaging-Market-to-2015.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... of the Diagnostic Imaging Market to 2015 , ...
Cached Medicine Technology:Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 2Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 3Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 4Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 5Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 6Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 7Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 8Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 9Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 10Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 11Reportlinker Adds The Future of the Diagnostic Imaging Market to 2015 12
(Date:8/27/2014)... 2014 New Jersey’s own Morgan Hoffmann ... County Club during The Barclays – and thanks to ... the tournament’s four rounds, stepped his way into raising ... Blue Shield of New Jersey (Horizon BCBNSNJ) Walking Challenge. ... native playing before family and friends at the Paramus ...
(Date:8/27/2014)... HealthDay Reporter WEDNESDAY, Aug. 27, ... a dark alley will likely never want to return there, ... But neuroscientists working with mice say they,ve discovered the ... and negative emotions. And in rodent tests, they,ve manipulated brain ... In essence, they made once-reluctant mice want to return to ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Ticket Down ... Chile tickets at Levi’s Stadium in Santa Clara. ... Santa Clara, California just opened in July and will host ... Mexico takes on Chile. These are two of the best ... 2014 World Cup and will look to continue their successes ...
(Date:8/27/2014)... key role in inflaming blood vessels and hardening arteries, ... UCLA demonstrates that they may also contribute to pulmonary ... blood vessels in the lungs. , Using a rodent ... of the main protein in high-density lipoprotein (HDL), the ... oxidized lipids in pulmonary hypertension. They also found that ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 ANS ... System, a ground breaking anti-cancer therapy for the treatment ... certified to prescribe this new medical therapy and will ... patients starting immediately. , NovoTTF™ Therapy is a portable, ... patients 22 years of age and older. It is ...
Breaking Medicine News(10 mins):Health News:Morgan Hoffmann, PGA TOUR Pro & Wyckoff Native, golfs and walks his way to top 10 finish at The Barclays while raising additional $7,500 for charity 2Health News:Scientists 'Rewrite' Bad Memories in Mice 2Health News:Scientists 'Rewrite' Bad Memories in Mice 3Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 2Health News:Mexico vs. Chile Tickets at Levi’s Stadium: Ticket Down Cuts Ticket Prices for Inaugural Soccer Match between Chile and Mexico in Santa Clara 3Health News:Protein in 'good cholesterol' may be a key to treating pulmonary hypertension 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 2Health News:Atlantic NeuroSurgical Specialists (ANS) Announces Availability of New Therapy for Brain Cancer 3
... BALTIMORE, Nov. 19 Care Improvement Plus, one of ... today,that it has received top scores from the Centers ... its structure and process measures. The,measures are the first ... SNPs in providing high quality care and improving health,outcomes ...
... , TORONTO, Nov. 19 /PRNewswire-FirstCall/ - ... development and commercialization of cancer therapies, announced today that ... II data from Neuradiab(TM) at the Society for Neuro-Oncology,s ... results from two previously conducted Phase II trials, is ...
... announced today that its “OneMedForum 2009” finance conference ... 13-14, 2009, in San Francisco at the Sir ... annual OneMedForum event is to be a vital ... Toward that end, the two-day OneMedForum event will ...
... innovator asks the regenerative medicine community: "Are Your Cells Free?" Learn more ... CA. , ... Fort Collins, CO (PRWEB) November 19, 2008 -- ... the 2008 North American Tissue Engineering Meeting TERMIS in San ...
... VTAL ), a leading provider of advanced ... its pioneering work in,developing advanced visualization and analysis software. ... and has continually advanced,the field of advanced visualization through ... "I have been ...
... Hearing to coincide with the 19th anniversary of the adoption of ... , ARLINGTON, Va., Nov. 19 ... Ratification of the Convention on the Rights of the Child (CRC), ... host a Senate Staff Briefing on Children,s Health Issues and The ...
Cached Medicine News:Health News:Care Improvement Plus Achieves Top Scores for First SNP Evaluation Measures 2Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 2Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 3Health News:Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting 4Health News: OneMedPlace announces "OneMedForum 2009" finance conference for emerging medtech companies : Second annual event to be held January 13-14, 2009, in San Francisco 2Health News:InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego 2Health News:Vital Images Celebrates Its 20th Anniversary 2Health News:Vital Images Celebrates Its 20th Anniversary 3Health News:Linda Spears, CWLA Vice President of Policy Will Speak at Senate Briefing 2
... Perfect Pupil Injectable was designed to provide the ... the risk of surgical complications during cataract and ... device for small and medium sized pupils which ... protects the iris sphincter during surgery, and allows ...
... Kojair Laminar Flow Unit is a flexible, ... air conditioning to operating theaters since 1983. A ... Our diverse and extensive experience from all the ... of the product , ,Kojair Tech Oy is ...
Provides stable positioning of the knee during surgery....
BRAT 2 Autologous Blood Recovery System gives performance, speed, versatility, and quality processing. , ,The BRAT 2 is now available with on-board Vacuum, programmability, plasma sequestration, Data...
Medicine Products: